PHLCX — PGIM Jennison Health Sciences Fund
Data updated: 2026-07-27
PHLCX — PGIM Jennison Health Sciences Fund data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $1.39B AUM · 1.97% expense ratio · 15.5% 1-yr return. From SEC regulatory filings.
PHLCX Fund Overview
PHLCX — PGIM Jennison Health Sciences Fund is a US mutual fund managed by Prudential Sector Funds, Inc., categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Prudential Sector Funds, Inc.
- Category: United States Health Care Equity
- Assets under management: $1.39B
- 1-year return: 15.5%
- Ticker: PHLCX
- SEC CIK: 0000352665
- SEC series ID: S000004380
- Share class ID: C000012123
PHLCX Holdings
Top 10 holdings of PGIM Jennison Health Sciences Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Eli Lilly & Company | 17.35% |
| Merck & Company, Inc. | 6.06% |
| Unitedhealth Group, Inc. | 5.87% |
| Thermo Fisher Scientific, Inc. | 4.56% |
| Argenx SE | 3.55% |
| Vertex Pharmaceuticals, Inc. | 3.37% |
| Danaher Corp. | 3.28% |
| Intuitive Surgical, Inc. | 3.07% |
| Lonza Group AG | 3.02% |
| Cvs Health Corp. | 2.52% |
PHLCX Portfolio Allocation
Asset-class allocation of PGIM Jennison Health Sciences Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 97.8% |
| Cash & Equivalents | 3.8% |
PHLCX Performance
Total returns for PHLCX (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 0.3% |
| 1 year | 15.5% |
| 3 years (annualised) | 13.4% |
| 5 years (annualised) | 6.1% |
PHLCX Risk Information
Risk metrics for PHLCX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 17.4%
PHLCX Costs and Fees
PHLCX costs about $197 per $10,000 invested per year in fund expenses.
- Net expense ratio: 1.97%
- Gross expense ratio: 1.97%
- Portfolio turnover: 81%
- Brokerage commissions: 6.92 bps of average net assets (SEC N-CEN)
PHLCX Cashflows
Over the 12 months to 2026-02, PGIM Jennison Health Sciences Fund had net outflows of $195.88M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-02 | −$14.99M |
| 2026-01 | −$17.15M |
| 2025-12 | $130.36M |
| 2025-11 | −$22.32M |
| 2025-10 | −$36.02M |
| 2025-09 | −$30.18M |
PHLCX Debt Constituents
No individual debt constituents are reported in PGIM Jennison Health Sciences Fund's latest SEC N-PORT filing.
PHLCX Prospectus and SEC Filings
Official PGIM Jennison Health Sciences Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.